Zaydfudim Victor M, Rosen Charles B, Nagorney David M
Department of Surgery, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, VA 22908, USA.
Division of Transplantation Surgery, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
Surg Oncol Clin N Am. 2014 Apr;23(2):247-63. doi: 10.1016/j.soc.2013.10.005.
Optimal treatment of hilar cholangiocarcinoma depends on location of the cancer and extent of biliary and vascular involvement. Candidates for resection or transplantation must be evaluated and managed by a multidisciplinary team at a high-volume hepatobiliary center. Success requires absence of distant nodal or extrahepatic metastases and an adequate functional liver remnant with a negative ductal margin. Ipsilateral portal vein resection and reconstruction should be performed in patients with venous involvement. Neoadjuvant chemoradiation and liver transplantation is the best treatment option for patients with unresectable hilar cholangiocarcinoma without nodal or distant metastases and for patients with underlying chronic liver disease.
肝门部胆管癌的最佳治疗方法取决于癌症的位置以及胆管和血管受累的程度。进行切除或移植的患者必须由大容量肝胆中心的多学科团队进行评估和管理。成功的关键在于无远处淋巴结或肝外转移,以及有足够功能的肝残余且切缘胆管阴性。对于有静脉受累的患者,应进行同侧门静脉切除和重建。新辅助放化疗和肝移植是无法切除的无淋巴结或远处转移的肝门部胆管癌患者以及伴有潜在慢性肝病患者的最佳治疗选择。